| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 13, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $6.00 → $2.00 | Buy → Hold | Craig Hallum |
| 12/3/2021 | $5.75 | Buy | Alliance Global Partners |
| 11/15/2021 | $6.00 | Buy | Craig-Hallum |
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
EFFECT - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter fiscal year 2024 ended June 30, 2024. Third Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $826,000 in Q3 2024, compared to $630,000 in Q3 2023Reduced operating expenses from $3.8 million in Q3 2023 to $3.1 million in Q3 2024Raised an additional $1.6 million using the ATM Program in Q3 2024Completed $2
EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update. Conference Call and Webcast Information: Wednesday, August 14, 2024 – 4:30 PM Eastern Time Participants: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 579769 Phone Replay:
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo® sEEG: Zimmer Biomet continued to expand into new a
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75
Craig-Hallum initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $6.00
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at
EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs. Mr. Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the Bracco Group, where he was the Vice President Quality Assurance. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Chad's appointment further strengthens our executive leadership team and deepens our capabilities as we build the pla
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS MarketsAgreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the execution of an amendment to its existing distribution agreement with Zimmer Biomet that will provide Zimmer Biomet with certain exclusive rights to distribute NeuroOne's OneRF™ Ablation System for use in the brain. NeuroOne will
EDEN PRAIRIE, Minn., Oct. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ron McClurg, CFO, will be presenting at 9:00 am ET on October 30th. The Company will also hold one-
Minimally invasive technology would allow for percutaneous placement of a paddle electrode Renowned pain specialist Dr. Sean Li to present on this innovative tool for lower back pain EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its percutaneous paddle technology will be featured at The Business of Pain Meeting September 26th – 29th at the Loew's Vanderbilt Hotel in Nashville, TN. Dr. Sean Li, course director and expert in pain manageme
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
Five ablations performed successfully in one patient Procedure performed at patient's bedside saving time and cost associated with the operating roomEDEN PRAIRIE, Minn., June 25, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used at a prestigious hospital located in Jacksonville, Florida to successfully complete five ablations in one patient.
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system